CurrentIndependent HealthPolicy M20160718056

Short-Term Glucose Monitoring

Defines medical necessity criteria and pre-authorization requirements for clinic‑owned, short-term (72-hour) continuous glucose monitoring used as an intermittent diagnostic and decision‑making tool for patients with diabetes; applies to Independent Health lines of business and specified state/plan products.

Policy Summary

PayerIndependent Health

PolicyShort-Term Glucose Monitoring

Policy CodePolicy M20160718056

Change TypeNo material change

Effective DateSep 1, 2016

Next Review Date

Key ActionObtain pre-authorization and document that the patient wore the short-term CGM for at least 72 hours with interstitial glucose readings every five minutes and at least four daily fingerstick checks.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

72 hrsmonitoring duration

5 minsampling frequency

≥4/dayfingerstick frequency

Requiredauthorization

Commercial/MA/SFlines covered

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Clinical Criteria for Short-Term CGM

Covered when ALL of the following are met:

Baseline requirements: Documentation that patient is performing finger stick glucose monitoring at least four times daily (or has a legitimate reason that such monitoring cannot be performed).

Baseline requirement applies to short-term CGM (72 hours).

Baseline requirements: Patient is an insulin‑requiring diabetic on insulin therapy.

Baseline requirement applies to short-term CGM (72 hours).

Indications (one or more required): Frequent episodes of hypoglycemia (<50 mg/dL); documented nocturnal hypoglycemia; significant disparity between blood glucose levels and HbA1c; hypoglycemia unawareness characterized by seizures or loss of consciousness; use of insulin pump; gastroparesis; early morning fasting hypoglycemia.

At least one of the listed indications must be present in addition to baseline requirements.

This policy applies to Independent Health Commercial, Self‑Funded and Medicare Advantage lines of business. MediSource, MediSource Connect and Child Health Plus follow the Commercial criteria for coverage of short‑term continuous glucose monitoring (CGM).

Coverage is limited to clinic‑owned, short‑term (intermittent) CGM used as a diagnostic and decision‑making tool and is subject to the medical necessity criteria and pre‑authorization requirements described in this policy.

Monitoring Parameters and Coding Notes

Monitoring duration / sampling frequency

Required monitoring duration72 hours (probe worn for at least 72 hours)

Sampling frequencyInterstitial fluid glucose recorded every 5 minutes during the 72-hour period

Data handlingAt completion probe is removed and monitor data are downloaded/printed for clinician review

Fingerstick monitoring frequency

Required fingerstick frequencyPatient must perform finger stick glucose monitoring at least four times daily

Allowable exceptionDocumentation may show a legitimate reason for inability to perform ≥4 finger sticks daily

Authorization, Documentation, and Billing Actions

Prior Authorization

Pre-authorization Required

Pre-authorization is required for short-term continuous glucose monitoring (CGM). The patient must meet the medical necessity criteria specified for a 72-hour short-term CGM (see Clinical Criteria Short-Term CGM).

Pre-authorization required for short-term CGM (72 hours).

Documentation Required

Documentation Requirement

Documentation should show the short-term CGM probe was inserted and worn for at least 72 hours with interstitial glucose recorded approximately every five minutes during the monitoring period. Records should include the downloaded report/printout used by the clinician to review and adjust the patient’s diet, exercise, and medication regimen.

Probe worn for at least 72 hours with glucose values recorded every ~5 minutes.
Downloaded monitor report/printout retained in the medical record and used for clinical decision-making.

Background

Short‑term (intermittent) CGM involves a clinic‑owned device with a subcutaneous probe worn by the patient for at least 72 hours that records interstitial glucose approximately every five minutes. Data are downloaded and reviewed by the clinician to identify patterns of hypoglycemia and hyperglycemia and to inform treatment decisions.

This modality is intended as a short‑term diagnostic and decision‑making tool—for example, when patients report suspected or feared hypoglycemia, when there is unexplained glycemic variability or discordance between blood glucose levels and HbA1c, or when hypoglycemia unawareness is suspected.

Patients must meet the policy’s baseline requirements, including being on insulin therapy and performing fingerstick glucose monitoring at least four times daily (or have a documented reason they cannot), and the procedure requires pre‑authorization; documentation should confirm the device was worn for at least 72 hours and that interstitial glucose was recorded at the stated sampling frequency.

Definitions

Short-term CGM definition

DefinitionShort-term continuous glucose monitoring (CGM) is a procedure where a probe is inserted subcutaneously and attached to a monitor worn by the patient for at least 72 hours

Recording frequencyThe interstitial fluid glucose is taken and recorded approximately every five minutes for the 72-hour period

Post-procedure processingAfter 72 hours the probe is removed and the monitor is connected to a computer to generate a printout of interstitial fluid glucose values for clinician review